Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC
UPPSALA, Sweden, Feb. 6, 2024 /PRNewswire/ — Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The presentation, entitled Bioavailability and Stability of an Epinephrine Nasal Powder Formulation for Treatment of Anaphylaxis, was selected by the AAAAI program committee to be presented at the late breaking oral abstract session.1, 2 Orexo’s advisor, Dr Anne K Ellis, Professor and Chair of the Division of Allergy & Immunology in the Department of Medicine at Queen’s University (Kingston, Ontario, CA) will give the presentation on behalf of Orexo. The AAAAI annual meeting is taking place in Washington, DC, February 23-26, 2024.
Related news for (ORXOY)
- Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
- Orexo AB´s sustainability work ranked among top 5% by EcoVadis
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds